Chunlin Chen, Ph.D. CEO of Shanghai Medicilon Inc.

Formally a Staff Investigator for Vertex Pharmaceuticals, Dr. Chen co-founded Medicilon in 2004. Dr Chen is a highly published thought leader in the pharmaceutical industry with extensive experience in academia, pharmaceutical, and regulatory evaluation. Dr. Chen received his PhD from Oklahoma State University, and completed postdoctoral training in the United States. He is a Postdoctoral Fellow at the St. Jude Children’s Research Hospital and has held numerous leadership positions in professional scientific trade organizations in China as well as other parts of the world. Dr. Chen has been awarded as special expert under national "Thousand Plan" program.

Guolin Wang, MBA, Chief Operating Officer of Shanghai Medicilon Inc.

Mr. Wang holds a masters degree in business administration from the open university of Hong Kong. Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom; and he served as General Manager in a health care investment company. He has rich experience on management and investment. 

Peter H Rehse Ph.D. Vice President of Biology, Shanghai Medicilon Inc . 

Peter Hugo Rehse, as Vice President of Medicilon since 2007. He has more than twenty year’s experience as a scientist specializing in macromolecular crystallography and analysis. He received Ph.D. in Crystallography from the University of London, England. Since gradation his projects have ranged from basic science to direct applications to the pharmaceutical industry conducted in internationally acclaimed facilities and institutes in Germany (Max Plank), Canada (NRC) and Japan (RIKEN).Just before joining Medicilon he worked for the RIKEN Protein 3000 project solving a large number of crystal structures.

Jun Wang, Ph.D. VP of Discovery Biology

Dr. Jun Wang, VP of Discovery Bioloigy at Shanhhai Medicilon.Inc., before joining Medicilon, Dr.Wang was VP and Head of Biology at Sundia MediTech. Dr. Wang served at Merck&Co., Inc. for 9 years leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company in Seattle as the head of biology section and served as an assistant professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has been invited by many corresponding author in leading scientific journals. Lately, Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, Naito Foundation etc. for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr. Wang got his BS in biophysics from Fudan University and received his Ph.D. in molecular biology and biochemistry from Kobe University (Japan). Post-doc training was followed in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).

Wencheng Lee, Ph.D. Vice President of Chemistry, Shanghai Medicilon Inc .

After finished his Chemistry BS degree in National Taiwan University, Dr. Lee went to University of Texas for doctorial degree training under the supervision of Prof. Stephan Martin, and then post-doctorial research at MIT under Prof. Masamune. Dr. Lee has more than 17 years of experience in drug discovery and development at Biogen Idec in US. Dr. Lee has led the small molecule project teams in the onco, immuno and neuro therapeutical areas. Several of those programs have advanced to clinical development. In addition, Dr. has extensive experience in operation and out sourcing.

Peng Cheng, Ph.D. Vice President of Chemistry, Shanghai Medicilon Inc .

Dr. Peng Cheng graduated from Peking University majoring in chemistry and obtained his Ph.D. in organic chemistry from New York University. He started his professional career with Tularik in California in 1999. From 2001 to 2007 he worked for Metabolex, a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases. From 2007 to 2011 Dr. Cheng Served as Senior Director of Chemistry and Assistant General Manager at Tianjin WuXi AppTec with increasing responsibilities. Dr. Cheng is well experienced in the field of drug discovery for the treatment of diabetes, dyslipidemia, obesity as well as inflammation. Three drug candidates resulted from his medichem programs have entered into various stages of clinical trials in the U.S. Dr. Cheng is also a veteran in enterprise management of Chinese CRO companies.

 Xingchu Gu, Ph.D. Executive Director & Test Facility Manager

Dr. Gu was Director of the Toxicology Research Department at the Shanghai Institute of Pharmaceutical Industry – China and Executive Director of the National Shanghai Center for New Drug Safety Evaluation and Research – China. He’s the GLP expert for the China State Food and Drug Administration. Dr. Gu was a visiting scholar in the German Houchst Pharmaceutical Company where he did drug preclinical research for two years. He also did short-term visits to GLP laboratories in United States, Canada and Australia. Dr. Gu was the project leader of 973 national projects and a total of 7 projects granted by National Youth New Drug Fund and the Science and Technology Commission of Shanghai Municipality-China. Dr. Gu also received the second price for Science and Technology Advancement awarded by the Shanghai Municipality-China. He is the member of China SFDA, GLP expert group and Chinese Society of Toxicology.